| Date Checked | 2026-02-19 22:15:29 |
|---|---|
| Graham Number | (PB)72.11 vs (PE)86.18 |
| Over / Under Value Percentage | 351.93% vs 332.42% |
| Dividend Yield | 2.75% |
| Dividend Date | 2026-03-06 |
| Symbol | AMGN |
| AssetType | Common Stock |
| Name | Amgen Inc |
| Description | Amgen Inc. is a leading multinational biopharmaceutical company headquartered in Thousand Oaks, California, recognized for its pioneering therapies developed through recombinant DNA technology. The company focuses on key therapeutic areas including oncology, nephrology, and inflammation, utilizing its deep expertise in molecular biology to create and commercialize innovative biologic products that significantly improve patient outcomes. With a comprehensive drug pipeline and a strong foothold in the biotechnology landscape, Amgen is dedicated to addressing global unmet medical needs while striving to enhance the quality of life for patients across the globe. Its commitment to research and development positions Amgen as a critical player in advancing medical science and improving health outcomes worldwide. |
| CIK | 318154 |
| Exchange | NASDAQ |
| Currency | USD |
| Country | USA |
| Sector | HEALTHCARE |
| Industry | DRUG MANUFACTURERS - GENERAL |
| Address | ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA, UNITED STATES, 91320-1799 |
| OfficialSite | https://www.amgen.com |
| FiscalYearEnd | December |
| LatestQuarter | 2025-09-30 |
| MarketCapitalization | 177757831000 |
| EBITDA | 16481000000 |
| PERatio | 25.51 |
| PEGRatio | 1.074 |
| BookValue | 17.86 |
| DividendPerShare | 9.39 |
| EPS | 12.94 |
| RevenuePerShareTTM | 66.89 |
| ProfitMargin | 0.195 |
| OperatingMarginTTM | 0.342 |
| ReturnOnAssetsTTM | 0.0771 |
| ReturnOnEquityTTM | 0.817 |
| RevenueTTM | 35970998000 |
| GrossProfitTTM | 25198000000 |
| DilutedEPSTTM | 12.94 |
| QuarterlyEarningsGrowthYOY | 0.136 |
| QuarterlyRevenueGrowthYOY | 0.124 |
| AnalystTargetPrice | 330.41 |
| AnalystRatingStrongBuy | 4 |
| AnalystRatingBuy | 10 |
| AnalystRatingHold | 15 |
| AnalystRatingSell | 2 |
| AnalystRatingStrongSell | 1 |
| TrailingPE | 25.51 |
| ForwardPE | 15.53 |
| PriceToSalesRatioTTM | 4.942 |
| PriceToBookRatio | 19.13 |
| EVToRevenue | 6.37 |
| EVToEBITDA | 13.86 |
| Beta | 0.45 |
| 52WeekHigh | 346.38 |
| 52WeekLow | 253.04 |
| 50DayMovingAverage | 325.89 |
| 200DayMovingAverage | 297.99 |
| SharesOutstanding | 538481000 |
| SharesFloat | 537129000 |
| PercentInsiders | 0.212 |
| PercentInstitutions | 84.027 |
| ExDividendDate | 2026-02-13 |
| dateChecked | 2026-02-19 22:15:29 |
| fresh | 1 |